Home › Companies › INOVIO PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed May 28, 2024 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of May 21, 2024: 10 items on INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed May 28, 2024: 10 without a stated outcome.
Meeting of January 12, 2024: 2 items on INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed January 12, 2024: 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore INOVIO PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are INOVIO PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. INOVIO PHARMACEUTICALS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Simon X. Benito | 3,735,000 | -- | -- | 325,511 | 7,564,931 | 92% | Not verified | — |
| Elect Director: Roger D. Dansey, M.D. | 3,752,771 | -- | -- | 307,740 | 7,564,931 | 92% | Not verified | — |
| Elect Director: Ann C. Miller, M.D. | 3,451,907 | -- | -- | 608,604 | 7,564,931 | 85% | Not verified | — |
| Elect Director: Jacqueline E. Shea, Ph.D. | 3,812,988 | -- | -- | 247,523 | 7,564,931 | 94% | Not verified | — |
| Elect Director: Jay P. Shepard | 3,760,672 | -- | -- | 299,839 | 7,564,931 | 93% | Not verified | — |
| Elect Director: David B. Weiner, Ph.D. | 3,819,190 | -- | -- | 241,321 | 7,564,931 | 94% | Not verified | — |
| Elect Director: Wendy L. Yarno | 3,106,384 | -- | -- | 954,127 | 7,564,931 | 77% | Not verified | — |
| Elect Director: Lota S. Zoth | 3,448,595 | -- | -- | 611,916 | 7,564,931 | 85% | Not verified | — |
| 2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 11,107,788 | 440,795 | 76,859 | -- | 0 | 96% | Not verified | — |
| 3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement | 3,001,768 | 946,999 | 111,744 | -- | 7,564,931 | 76% | Not verified | — |
Source: INOVIO PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 28, 2024 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Reverse Stock Split Proposal | 96,534,629 | 48,857,255 | 874,089 | -- | -- | 66% | Approved | — |
| 2. Adjournment Proposal | 106,842,257 | 37,097,854 | 2,325,862 | -- | -- | 74% | Approved | — |
Source: INOVIO PHARMACEUTICALS INC., Form 8-K, filed with the SEC on January 12, 2024 — read the filing on EDGAR.
Each item below shows how the 110 asset managers that disclosed a INOVIO PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 3,451,907 for, 608,604 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,448,418 for, 29,463 withheld, 375 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 11,075 | Withhold |
| American Century | 0 | 0 | 0 | 9,436 | Withhold |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 4,938 | Withhold |
| Nationwide | 0 | 0 | 0 | 2,776 | Withhold |
| Invesco | 0 | 0 | 0 | 1,033 | Withhold |
| John Hancock | 0 | 0 | 375 | 0 | Abstain |
| Guggenheim | 0 | 0 | 0 | 205 | Withhold |
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 3,819,190 for, 241,321 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,478,256 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 11,075 | 0 | 0 | 0 | For |
| American Century | 9,436 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 4,938 | 0 | 0 | 0 | For |
| Nationwide | 2,776 | 0 | 0 | 0 | For |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 375 | 0 | 0 | 0 | For |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Meeting held May 21, 2024.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 3,812,988 for, 247,523 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,478,256 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 11,075 | 0 | 0 | 0 | For |
| American Century | 9,436 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 4,938 | 0 | 0 | 0 | For |
| Nationwide | 2,776 | 0 | 0 | 0 | For |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 375 | 0 | 0 | 0 | For |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay P. Shepard”): 3,760,672 for, 299,839 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,478,256 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 11,075 | 0 | 0 | 0 | For |
| American Century | 9,436 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 4,938 | 0 | 0 | 0 | For |
| Nationwide | 2,776 | 0 | 0 | 0 | For |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 375 | 0 | 0 | 0 | For |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lota S. Zoth”): 3,448,595 for, 611,916 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,449,451 for, 28,430 withheld, 375 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 11,075 | Withhold |
| American Century | 0 | 0 | 0 | 9,436 | Withhold |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 4,938 | Withhold |
| Nationwide | 0 | 0 | 0 | 2,776 | Withhold |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 375 | 0 | Abstain |
| Guggenheim | 0 | 0 | 0 | 205 | Withhold |
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 3,752,771 for, 307,740 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,478,256 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 11,075 | 0 | 0 | 0 | For |
| American Century | 9,436 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 4,938 | 0 | 0 | 0 | For |
| Nationwide | 2,776 | 0 | 0 | 0 | For |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 375 | 0 | 0 | 0 | For |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Simon X. Benito”): 3,735,000 for, 325,511 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,464,407 for, 7,598 withheld, 6,251 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 11,075 | 0 | 0 | 0 | For |
| American Century | 9,436 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 0 | 0 | 5,876 | 0 | Abstain |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 4,938 | Withhold |
| Nationwide | 116 | 0 | 0 | 2,660 | Withhold |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 375 | 0 | Abstain |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 3,106,384 for, 954,127 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,448,418 for, 29,463 withheld, 375 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 11,075 | Withhold |
| American Century | 0 | 0 | 0 | 9,436 | Withhold |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 4,938 | Withhold |
| Nationwide | 0 | 0 | 0 | 2,776 | Withhold |
| Invesco | 0 | 0 | 0 | 1,033 | Withhold |
| John Hancock | 0 | 0 | 375 | 0 | Abstain |
| Guggenheim | 0 | 0 | 0 | 205 | Withhold |
Meeting held January 12, 2024.
Combines 3 wordings of this item as funds reported it.
66% Approved · of votes cast
Description as filed by funds: To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for 10 shares up to a ratio of 1-for 50 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“1. Reverse Stock Split Proposal”): 96,534,629 for, 48,857,255 against — passed, per its Form 8-K filed January 12, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Reverse Stock Split Proposal was approved.”
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 21,351,918 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,639,916 | 0 | 0 | 0 | For |
| BlackRock | 902,050 | 0 | 0 | 0 | For |
| Fidelity | 235,732 | 0 | 0 | 0 | For |
| Invesco | 157,750 | 0 | 0 | 0 | For |
| Charles Schwab | 132,910 | 0 | 0 | 0 | For |
| Legg Mason | 93,972 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 77,447 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 57,651 | 0 | 0 | 0 | For |
| Victory Capital | 29,100 | 0 | 0 | 0 | For |
| ProShares | 16,671 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 5,000 | 0 | 0 | 0 | For |
| Guggenheim | 2,464 | 0 | 0 | 0 | For |
| Nationwide | 1,255 | 0 | 0 | 0 | For |
Meeting held January 12, 2024.
Combines 2 wordings of this item as funds reported it.
74% Approved · of votes cast
Description as filed by funds: To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“2. Adjournment Proposal”): 106,842,257 for, 37,097,854 against — passed, per its Form 8-K filed January 12, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Adjournment Proposal”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 21,351,918 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,639,916 | 0 | 0 | 0 | For |
| BlackRock | 902,050 | 0 | 0 | 0 | For |
| Fidelity | 235,732 | 0 | 0 | 0 | For |
| Invesco | 157,750 | 0 | 0 | 0 | For |
| Charles Schwab | 132,910 | 0 | 0 | 0 | For |
| Legg Mason | 93,972 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 77,447 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 57,651 | 0 | 0 | 0 | For |
| Victory Capital | 29,100 | 0 | 0 | 0 | For |
| ProShares | 16,671 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 5,000 | 0 | 0 | 0 | For |
| Guggenheim | 2,464 | 0 | 0 | 0 | For |
| Nationwide | 1,255 | 0 | 0 | 0 | For |
Meeting held May 21, 2024.
Combines 9 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 3,001,768 for, 946,999 against, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 0 | 62,912 | 0 | 0 | Against |
| Charles Schwab | 0 | 11,075 | 0 | 0 | Against |
| American Century | 0 | 9,436 | 0 | 0 | Against |
| Amplify ETF Trust | 5,876 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 4,938 | 0 | 0 | Against |
| Nationwide | 0 | 2,776 | 0 | 0 | Against |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 0 | 375 | 0 | 0 | Against |
| Guggenheim | 0 | 205 | 0 | 0 | Against |
Fund voting reports, all 10 managers: 1,386,539 for, 91,717 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Baron Financial Group, LLC | 4,100,000 | 0 | 0 | 0 | For |
| BlackRock | 246,029 | 2,660 | 0 | 0 | For |
| Renaissance | 0 | 191,880 | 0 | 0 | Against |
| State Street | 88,681 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 66,838 | 0 | 0 | Against |
| Northern Trust | 24,728 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 17,916 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 16,497 | 0 | 0 | Against |
| T. Rowe Price | 0 | 12,499 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 12,118 | 0 | 0 | Against |
| Two Sigma | 0 | 11,983 | 0 | 0 | Against |
| Charles Schwab | 0 | 11,075 | 0 | 0 | Against |
| CIBC Private Wealth Group LLC | 0 | 10,358 | 0 | 0 | Against |
| American Century | 0 | 9,436 | 0 | 0 | Against |
| Fidelity | 9,257 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 7,854 | 0 | 0 | Against |
| Vanguard | 7,580 | 0 | 0 | 0 | For |
| Corient Private Wealth LLC | 0 | 6,813 | 0 | 0 | Against |
| OMERS ADMINISTRATION Corp | 0 | 6,400 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 0 | 4,938 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 4,450 | 0 | 0 | Against |
| Dimensional | 0 | 4,016 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 1,828 | 0 | 0 | Against |
| First Affirmative Financial Network | 0 | 1,734 | 0 | 0 | Against |
| Natixis | 0 | 1,636 | 0 | 0 | Against |
No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.
Meeting held May 21, 2024.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
INOVIO PHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 11,107,788 for, 440,795 against, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 1,472,380 for, 5,876 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,379,630 | 0 | 0 | 0 | For |
| Fidelity | 62,912 | 0 | 0 | 0 | For |
| Charles Schwab | 11,075 | 0 | 0 | 0 | For |
| American Century | 9,436 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 0 | 5,876 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 4,938 | 0 | 0 | 0 | For |
| Nationwide | 2,776 | 0 | 0 | 0 | For |
| Invesco | 1,033 | 0 | 0 | 0 | For |
| John Hancock | 375 | 0 | 0 | 0 | For |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 25,910,701 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 75.80% |
| 2 | BlackRock | 3.48% |
| 3 | Fidelity | 0.91% |
| 4 | Invesco | 0.61% |
| 5 | Charles Schwab | 0.51% |
| 6 | Legg Mason | 0.36% |
| 7 | Amplify ETF Trust | 0.30% |
| 8 | Principal Exchange-Traded Funds | 0.22% |
| 9 | Victory Capital | 0.11% |
| 10 | ProShares | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Baron Financial Group, LLC | 15.82% |
| 2 | BlackRock | 0.96% |
| 3 | Renaissance | 0.74% |
| 4 | State Street | 0.34% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.26% |
| 6 | Northern Trust | 0.10% |
| 7 | PNC BANK, NATIONAL ASSOCIATION | 0.07% |
| 8 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.06% |
| 9 | T. Rowe Price | 0.05% |
| 10 | HighTower Advisors, LLC | 0.05% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 10.47% | 13F |
| Morgan Stanley | 3.04% | 13F |
| BlackRock | 1.93% | 13F |
| Renaissance Technologies | 1.74% | 13F |
| Millennium Management | 1.03% | 13F |
| Geode Capital | 0.97% | 13F |
| State Street | 0.34% | 13F |
| Citadel Advisors | 0.29% | 13F |
| JPMorgan Chase | 0.25% | 13F |
| Goldman Sachs | 0.21% | 13F |
Percentages above are of 25,910,701 shares outstanding, as reported by INOVIO PHARMACEUTICALS INC. on its Form 10-Q dated May 10, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INOVIO PHARMACEUTICALS INC.’s 10-Q dated May 10, 2024. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At INOVIO PHARMACEUTICALS INC.'s 2 shareholder meetings in the 2023-2024 proxy season (held January 12, 2024 and May 21, 2024), 110 asset managers reported how they voted on 12 ballot items in their SEC Form N-PX filings, covering 397 separate fund positions. On the most widely held item of the season, voted at the meeting held May 21, 2024 — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 76% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: INOVIO PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2024.
INOVIO PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.